Quantifying cancer- and drug-induced changes in Shannon information capacity of RTK signaling

Paweł Nałęcz-Jawecki1, Lee Roth2, Frederic Grabowski1

  • 1Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland.

Insights

Cancer disrupts cellular communication by reducing information capacity in signaling pathways. Inhibiting oncogenes improved information flow in lung cancer cells, but capacity remained lower than in healthy cells, revealing a new metric for disease assessment.

Area of Science:

  • Cellular signaling and information theory
  • Quantitative analysis of biological systems

Background:

  • Cellular signaling pathways transmit external cues for accurate cell response.
  • Cancer can impair signal transmission, but the impact on information capacity is unquantified.

Purpose of the Study:

  • To quantify and compare information capacity in receptor tyrosine kinase (RTK) signaling pathways.
  • To assess the impact of oncogene-driven cancer on cellular information processing.
  • To evaluate the efficacy of targeted interventions using information capacity as a metric.

Main Methods:

  • Utilized pseudo-random pulsatile optogenetic stimulation and live-cell imaging.
  • Applied information theory to measure information rate and channel capacity.
  • Employed in silico protocol optimization to estimate maximum information rates.

Main Results:

  • RTK/ERK pathway information rate in lung cancer cells (STE-1) was low (<0.5 bit/hour), increasing to 3 bit/hour after oncogene inhibition.
  • Information transmission occurred in only 50-70% of cancer cells.
  • Oncogene inhibition increased STE-1 cell RTK/ERK pathway capacity to 6 bit/hour, still lower than in healthy BEAS-2B cells (11 bit/hour).
  • The RTK/calcineurin pathway in BEAS-2B cells demonstrated a capacity exceeding 15 bit/hour.

Conclusions:

  • Information capacity is a sensitive indicator of disease-associated signaling dysfunction.
  • Targeted oncogene inhibition can partially restore signaling pathway capacity.
  • This approach offers a novel method for evaluating therapeutic interventions in cancer.

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...